Table 2. Differences in the distribution of variables between oligometastatic state and non-oligometastatic state.
| Variables | Oligometastasis | p value | |
|---|---|---|---|
| yes | no | ||
| All patients | 22(32.8%) | 45(67.2%) | |
| Gender | |||
| male | 18(81.8%) | 33(73.3%) | 0.757 |
| female | 4(18.2) | 11(26.7) | |
| Age (Years) | |||
| ≥58 | 10(45.5%) | 27(60.0%) | 0.303 |
| <58 | 12(54.5%) | 18(40.0%) | |
| MSKCC score | |||
| Low risk | 13(59.1%) | 20(44.4%) | 0.141 |
| Intermediate risk | 8(36.4%) | 23(51.1%) | |
| High risk | 1(4.5%) | 2(4.5%) | |
| ECOG | |||
| 0 | 15(68.2%) | 32(71.2%) | 0.568 |
| 1 | 7(31.8%) | 10(22.2%) | |
| 2 | 0 | 1(2.2%) | |
| 3 | 0 | 2(4.4%) | |
| DFI | |||
| ≥1y | 13(59.1%) | 22(48.9%) | 0.45 |
| <1y | 9(40.9%) | 23(51.1%) | |
| Hemoglobin | |||
| High | 17(77.3%) | 37(82.2%) | 0.745 |
| Low | 5(22.7%) | 8(17.8%) | |
| Corrected calcium | |||
| ≤10 mg/dL | 22(100%) | 43(95.6%) | 1 |
| >10 mg/dL | 0(0%) | 2(4.4%) | |
| LDH | |||
| High | 0(0%) | 6(13.3%) | 0.167 |
| Low | 22(100%) | 39(86.7%) | |
| Skeletal related events | |||
| YES | 9(40.9%) | 37(82.2%) | 0.002 |
| No | 13(59.1%) | 8(17.8%) | |
| Dose reduction | |||
| Yes | 12(54.5%) | 13(28.9%) | 0.06 |
| No | 10(45.5%) | 32(71.1%) | |
Abbreviations: MSKCC=Memorial Sloan Kettering Cancer Center; ECOG=Eastern Cooperative Oncology Group; DFI = disease-free interval; LDH = lactate dehydrogenase